TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04241133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The UnProcessed Pantry Project (UP3)
Description: UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
Study: NCT01104090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC direct laryngoscopy
Description: Patients will be intubated using C-MAC with direct laryngoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC direct laryngoscopy
Description: Patients will be intubated using C-MAC with direct laryngoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC Indirect laryngoscopy
Description: Patients will be intubated using C-MAC with indirect laryngoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC Indirect laryngoscopy
Description: Patients will be intubated using C-MAC with indirect laryngoscopy.
Study: NCT00151216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2CUhCLN2 (3x10^12 particle units)
Description: gene transfer; one-time administration via neuro surgery procedure

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2CUhCLN2 (3x10^12 particle units)
Description: gene transfer; one-time administration via neuro surgery procedure
Study: NCT03936933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate 3.6 mg Injection
Description: 3.6 mg, Subcutaneously at every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOLADEX® 3.6mg Injection
Description: 3.6 mg, Subcutaneously at every 28 days
Study: NCT01755117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic, femoral, obturator nerve blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block, posterior lumbar plexus block
Study: NCT04421976

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEEP
Description: Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
Study: NCT00551616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDB-2914
Description: Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: Single dose
Study: NCT04244006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Prefilled Syringe
Description: administration of dupilumab corresponding to dupilumab arm
Study: NCT04148924

Intervention type: OTHER
Intervention: Medical staff questionnaire
Description: Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms
Study: NCT01380106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide 15mg
Description: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide 25mg
Description: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
Study: NCT02422927

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Combination
Description: red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00965705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Individual Therapy and Group Therapy
Study: NCT04016714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaxelis™
Description: Intramuscular 0.5 mL single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxelis™
Description: Intramuscular 0.5 mL single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: Subcutaneous 0.5 mL single dose
Study: NCT04606251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
Study: NCT00290732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraductal arm
Description: Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous arm
Description: Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
Study: NCT00548119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoCart
Description: autologous tissue implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfracture
Description: microfracture
Study: NCT00964366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin and benzoyl peroxide
Description: Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone gel
Description: Twice-daily applications of dapsone gel
Study: NCT02116829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Danish butter
Description: The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Study: NCT02887313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
Study: NCT02909699

Intervention type: OTHER
Intervention: Observation
Description: In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.

Intervention type: OTHER
Intervention: Observation
Description: In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
Study: NCT04016714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-M-R®II
Description: Subcutaneous 0.5 mL single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™
Description: Subcutaneous 0.5 mL single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: Subcutaneous 0.5 mL single dose
Study: NCT01772654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Spin Labeled (ASL) MRI sequence
Description: The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeled (ASL) MRI sequence
Description: The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence.
Study: NCT00895505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Phenprocoumon 3 mg, tablet, INR adjusted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin-Natrium
Description: Warfarin-Natrium 5 mg, tablet, INR adjusted
Study: NCT03814759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 + cisplatin
Description: S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation 45Gy per 5 weeks
Study: NCT01706185

Intervention type: OTHER
Intervention: Data acquisition and analysis
Description: Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
Study: NCT00572819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
Study: NCT03225404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epte group
Description: Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling group
Description: The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
Study: NCT00855101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: 6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
Study: NCT01441492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drains
Description: A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
Study: NCT03922997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
Study: NCT02909699

Intervention type: OTHER
Intervention: Observation
Description: In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
Study: NCT01183533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (iv t-PA)
Description: 0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
Study: NCT02034149

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: general management
Description: All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general management
Description: All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general management
Description: All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management
Description: Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management
Description: Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
Study: NCT01441492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drains
Description: A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
Study: NCT05663684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Description: One drop instilled in one eye, randomly chosen, as control placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Description: One drop instilled in one eye, randomly chosen, as control placebo
Study: NCT00965705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Individual Therapy and Group Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Individual Therapy and Group Therapy
Study: NCT03573050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIV-TDS 13.3 mg/24 h
Description: 5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon® 13.3 mg/24 hours transdermal patch
Description: 5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
Study: NCT00967499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery.
Study: NCT01596114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping treatment with TKI
Description: stopping until loss of MMR
Study: NCT02270814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study: NCT02340819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
Study: NCT02053389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Decision Aid
Description: The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation.
Study: NCT02270814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT03711734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture + Standard of Care
Description: Acupuncture is a nonpharmacologic pain management modality that has been shown to provide superior analgesia for acute pain. This will be combined with our facility's standard of care anesthesia and pain management plan.
Study: NCT03782207

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
Study: NCT03687957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-7-hyFc
Description: -Given by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-7-hyFc
Description: -Given by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-7-hyFc
Description: -Given by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: -Given by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Standard of care
Study: NCT03565978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAMA solution
Description: Use of BAMA cardiac post-discharge management solution for patients education and follow up management